Drug intelligence / Profile preview

arbaprostil

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Arbaprostil is a synthetic analog of prostaglandin E2 (PGE2), specifically the 15(R)-methyl derivative. Developed by Upjohn, it acts as a gastric cytoprotective agent and an inhibitor of gastric acid secretion. It was primarily investigated for the prevention and healing of gastric mucosal damage and ulcers associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with conditions like rheumatoid arthritis and osteoarthritis. Clinical trials demonstrated its efficacy in resolving gastric lesions, though its use was associated with dose-dependent diarrhea. Development was eventually discontinued in favor of other prostaglandin analogs like misoprostol.

Other names: 15(R)-15-methylprostaglandin E215-methyl-PGE215(R)-15-methyl-PGE2

Targets

PTGER2 (Prostaglandin E2 receptor EP2)

Beyond the preview

Go deeper on arbaprostil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on arbaprostil.

Explore the full profile